How are energy investors positioned?
On Monday, Cantor Fitzgerald confirmed its Overweight rating on Sanara MedTech shares, maintaining a $45.00 price target. The affirmation follows Sanara MedTech’s first-quarter financial report for 2025, which was released on May 14, 2025. Sanara MedTech, which trades under the ticker (NASDAQ:SMTI), showcased a year-over-year revenue growth of approximately 26%, with earnings of $23.4 million. This figure surpassed the FactSet consensus estimate of $22.3 million but fell slightly short of Cantor’s projection of $24.7 million. According to InvestingPro data, the company maintains impressive gross profit margins of 91% and has achieved a robust trailing twelve-month revenue growth of 35%.
The revenue increase was attributed to heightened sales of the company’s soft tissue repair products. Throughout the 12-month period concluding at the end of the first quarter in 2025, Sanara MedTech’s products were sold in over 1,300 facilities. This marks a significant rise from the 1,080 facilities recorded in the previous year. InvestingPro analysis shows the company operates with a healthy current ratio of 2.77, indicating strong liquidity to support its expansion. Subscribers can access 5 additional ProTips and comprehensive financial metrics on the platform.
In addition to the expanded facility presence, Sanara MedTech has also broadened its market reach within the healthcare sector. As of March 31, 2025, the company’s products were either contracted or approved for sale in more than 4,000 hospitals and ambulatory surgery centers (ASCs). This expansion is indicative of the company’s growing influence and presence in the medical products market.
The sustained Overweight rating by Cantor Fitzgerald suggests confidence in Sanara MedTech’s growth trajectory and its ability to maintain a strong position within its industry. The $45.00 price target set by Cantor reflects an expectation of continued performance and market penetration by the company.
Sanara MedTech’s recent financial outcomes and strategic expansions demonstrate its commitment to increasing its market share and continuing its growth momentum in the medical technology sector. The company’s performance and the optimistic outlook by analysts like those at Cantor Fitzgerald could be of interest to investors monitoring the healthcare industry.
In other recent news, Sanara MedTech reported its first-quarter financial results for 2025, revealing a net revenue of $23.4 million, which represents a 26% increase year-over-year. Despite this growth, the company experienced a net loss of $3.5 million, or $0.41 per share, missing the earnings per share (EPS) forecast of -$0.265. Revenue also fell short of the anticipated $24.1 million. The company’s soft tissue repair segment, including products like CellerateRX Surgical Activated Collagen, saw a notable 28% increase, contributing $20.5 million to the revenue. Bone fusion products also contributed positively, with an 18% rise in revenue to $2.9 million.
H.C. Wainwright analyst Yi Chen responded to these developments by raising the price target for Sanara MedTech to $53 from $51, while maintaining a Buy rating. Chen highlighted the potential for further growth in Sanara’s Surgical segment, supported by the expansion of its sales team and distribution network. Gross margins improved by 240 basis points to 92%, and adjusted EBITDA increased by 111% to $700,000, showcasing operational efficiency gains. Sanara MedTech continues to focus on expanding its distributor network and penetrating new and existing healthcare facilities to drive future growth.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.